Sinclair, a global aesthetics leader, announced the appointment of Dr. Ryan Irvine as its new Chief Development Officer. This strategic move underscores Sinclair’s unwavering commitment to becoming the preeminent leader in the US market and revolutionizing the aesthetics industry.
Sinclair, a global aesthetics leader, today announced the appointment of Dr. Ryan Irvine as its new Chief Development Officer. This strategic move underscores Sinclair’s unwavering commitment to becoming the preeminent leader in the US market and revolutionizing the aesthetics industry.
Dr. Irvine, a seasoned biotechnology veteran with a distinguished career in aesthetics, joins Sinclair at a pivotal moment. His extensive experience in developing and commercializing groundbreaking products like BOTOX, Juvéderm, and Kybella positions him perfectly to spearhead Sinclair’s US expansion and propel its innovative portfolio forward. “We are thrilled to welcome Dr. Ryan Irvine to our team,” said Miguel Pardos, CEO Sinclair. “Dr. Irvine brings a wealth of experience and expertise in the field of neurotoxin, and we are confident that his contributions will be instrumental in driving our mission forward. His innovative approach and dedication to excellence align perfectly with our core values, and we look forward to the positive impact he will have on our organization.”
Dr. Irvine will be based in Los Angeles, California, and will oversee all aspects of clinical development for Sinclair’s product portfolio. This includes securing US regulatory approvals for all new Sinclair products, including the highly anticipated botulinum toxin ATGC-110. Additionally, he will spearhead the effort to secure US regulatory approvals for Sinclair’s top performing injectables: Ellansé, a PCL-based collagen stimulator, and Maili, a next-generation hyaluronic acid filler.
This appointment comes on the heels of Sinclair’s strategic acquisitions, including Viora and its advanced, non-invasive energy-based devices. This move not only bolstered Sinclair’s technology portfolio but also established a vital direct commercial presence in the US. Additionally, Sinclair’s global licensing agreement with ATGC for ATGC-110 solidified its position as a global leader in aesthetics.
